Response Genetics Announces Resignation of CFO
Response Genetics, a company focused on the development and sale of molecular diagnostic tests for cancer, has announced that Thomas Stankovich has resigned from his position as chief financial officer (CFO) to pursue other interests. Stankovich will complete the filing of the company’s 2009 Annual Report on Form 10-K and has agreed to be available beyond his resignation date to assist in the transition of his role.
The company has commenced a search for a new CFO. In the interim, Eric Alcorn, vice president of finance and administration, will assume Stankovich’s responsibilities. Alcorn has been with the company since its inception.
Stankovich joined Response Genetics in November 2006. He has been responsible for management of the company’s finance functions, strategic planning and administrative services.